The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2018 | Tailoring treatment in CLL using predictive markers
The management of chronic lymphocytic leukemia (CLL) has progressed dramatically, moving into an era of tailored treatment. Here, Alessandra Tedeschi, MD, PhD, of the Niguarda Cancer Center, Milan, Italy, speaking from the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain, discusses the tailoring of CLL treatment using a variety of predictive factors, including 17p deletion and IGHV mutation. Dr Tedeschi also adresses a number of current concerns, such as the limited number of salvage therapy options in this space.
